Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Given Average Recommendation of "Moderate Buy" by Analysts
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Given Average Recommendation of "Moderate Buy" by Analysts
Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA – Get Rating) have earned a consensus recommendation of "Moderate Buy" from the nine ratings firms that are covering the firm, Marketbeat.com reports. Four research analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $78.63.
据Marketbeat.com报道，埃南塔制药公司(纳斯达克代码：ENTA-GET Rating)的股票获得了涵盖该公司的九家评级公司的共识建议，即“适度买入”。四位研究分析师对该股的评级为持有建议，四位分析师给该公司指定了买入建议。过去一年对该股进行评级的经纪商的平均12个月目标价为78.63美元。
A number of equities research analysts recently weighed in on ENTA shares. Oppenheimer increased their price target on Enanta Pharmaceuticals from $53.00 to $59.00 and gave the company a "market perform" rating in a research note on Wednesday, August 10th. StockNews.com upgraded Enanta Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Wednesday, August 10th. Evercore ISI raised Enanta Pharmaceuticals from an "in-line" rating to an "outperform" rating and set a $62.00 price objective on the stock in a report on Wednesday, July 6th. JMP Securities upped their price objective on Enanta Pharmaceuticals from $103.00 to $137.00 and gave the company a "market outperform" rating in a report on Tuesday, August 9th. Finally, Royal Bank of Canada decreased their price objective on Enanta Pharmaceuticals from $67.00 to $66.00 and set a "sector perform" rating on the stock in a report on Tuesday, August 9th.
许多股票研究分析师最近纷纷买入Enta的股票。8月10日，周三，奥本海默在一份研究报告中将他们对Enanta PharmPharmticals的目标价从53.00美元上调至59.00美元，并给予该公司“市场表现”评级。在8月10日星期三的一份研究报告中，StockNews.com将Enanta PharmPharmticals的评级从“卖出”上调至“持有”。Evercore ISI在7月6日(星期三)的一份报告中将Enanta PharmPharmticals的评级从“在线”上调至“表现优于大盘”，并为该股设定了62.00美元的目标价。JMP证券在8月9日周二的一份报告中将Enanta PharmPharmticals的目标价从103.00美元上调至137.00美元，并给予该公司“市场表现优于大盘”的评级。最后，加拿大皇家银行在8月9日(星期二)的一份报告中将他们对Enanta PharmPharmticals的目标价从67.00美元下调至66.00美元，并对该股设定了“行业表现”评级。
Enanta Pharmaceuticals Trading Down 0.1 %
Enanta制药公司股价下跌0.1%
ENTA opened at $52.65 on Friday. Enanta Pharmaceuticals has a 1-year low of $37.59 and a 1-year high of $102.00. The stock's fifty day simple moving average is $60.55 and its 200 day simple moving average is $58.09. The stock has a market cap of $1.09 billion, a PE ratio of -8.98 and a beta of 0.55.
Enta上周五开盘报52.65美元。Enanta PharmPharmticals的一年低点为37.59美元，一年高点为102.00美元。该股的50日简单移动均线为60.55美元，200日简单移动均线为58.09美元。该股市值为10.9亿美元，市盈率为-8.98，贝塔系数为0.55。
Hedge Funds Weigh In On Enanta Pharmaceuticals
对冲基金买入Enanta制药
Large investors have recently bought and sold shares of the company. RA Capital Management L.P. bought a new position in shares of Enanta Pharmaceuticals during the first quarter worth about $68,633,000. State Street Corp raised its position in shares of Enanta Pharmaceuticals by 29.9% during the second quarter. State Street Corp now owns 1,699,428 shares of the biotechnology company's stock worth $80,332,000 after acquiring an additional 390,842 shares during the last quarter. Deep Track Capital LP bought a new stake in Enanta Pharmaceuticals in the first quarter worth approximately $14,146,000. Invesco Ltd. increased its holdings in Enanta Pharmaceuticals by 173.0% in the fourth quarter. Invesco Ltd. now owns 289,844 shares of the biotechnology company's stock worth $21,674,000 after purchasing an additional 183,676 shares in the last quarter. Finally, Darwin Global Management Ltd. bought a new stake in Enanta Pharmaceuticals in the fourth quarter worth approximately $12,428,000. 97.09% of the stock is currently owned by institutional investors.
大型投资者最近买卖了该公司的股票。Ra Capital Management L.P.在第一季度购买了价值约6863.3万美元的Enanta制药公司的新股票头寸。道富集团在第二季度将其在Enanta PharmPharmticals的股票头寸提高了29.9%。道富集团目前持有这家生物技术公司1,699,428股股票，价值80,332,000美元，此前该公司在上个季度又收购了390,842股。Deep Track Capital LP在第一季度购买了Enanta PharmPharmticals的新股份，价值约14,146,000美元。景顺在第四季度增持了173.0%的Enanta PharmPharmticals股份。景顺公司目前持有289,844股这家生物技术公司的股票，价值21,674,000美元，上个季度又购买了183,676股。最后，达尔文全球管理有限公司在第四季度购买了价值约12,428,000美元的Enanta制药公司的新股份。97.09%的股票目前由机构投资者持有。
About Enanta Pharmaceuticals
关于Enanta制药公司
(Get Rating)
(获取评级)
Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus.
Enanta制药公司是一家生物技术公司，发现和开发用于治疗病毒感染和肝病的小分子药物。其研发的疾病靶标包括呼吸道合胞病毒、SARS-CoV-2、人类偏肺病毒和乙肝病毒。该公司与雅培签订了一项合作开发和许可协议，以识别、开发和商业化丙型肝炎病毒NS3和NS3/4A蛋白酶抑制剂化合物，包括用于治疗慢性丙型肝炎病毒的paritaprevir和glecapvir。
See Also
另请参阅
- Get a free copy of the StockNews.com research report on Enanta Pharmaceuticals (ENTA)
- The Institutions Hold On To Darden Restaurants International
- What Steelcase's Earnings Say About the Return to the Office?
- Is The Golden Age Of Homebuilding Already Over?
- These 3 Big Dividend Payers Also Boast Strong Price Growth
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- 免费获取StockNews.com关于Enanta制药公司(Enta)的研究报告
- 这些机构持有达顿餐饮国际公司的股份
- 斯蒂尔凯斯的收益说明了他重返办公室的原因吗？
- 住房建设的黄金时代已经结束了吗？
- 这三大股利支付者也拥有强劲的价格增长
- 天然气价格继续回升，这些股票应该会受益
Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
接受Enanta制药日报的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Enanta制药和相关公司的最新新闻和分析师评级的每日简要摘要。